Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cassiopea SpA    SKIN   IT0005108359

CASSIOPEA SPA

(SKIN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
03/15/2019 03/18/2019 03/19/2019 03/20/2019 03/21/2019 Date
46.2(c) 45.1(c) 46(c) 43.9(c) 44.4(c) Last
2 197 3 930 712 4 012 5 403 Volume
+5.72% -2.38% +2.00% -4.57% +1.14% Change
More quotes
Financials (EUR)
Sales 2019 -
EBIT 2019 -18,5 M
Net income 2019 -18,0 M
Debt 2019 18,3 M
Yield 2019 -
Sales 2020 59,7 M
EBIT 2020 -6,93 M
Net income 2020 -12,0 M
Debt 2020 16,8 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 0
EV / Sales2020 6,87x
Capitalization 394 M
More Financials
Company
Cassiopea SpA is an Italy-based company engaged in the biotechnology and medical research industry. The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. The Company's current focus is... 
Sector
Pharmaceuticals
Calendar
07/19Earnings Release
More about the company
Latest news on CASSIOPEA SPA
03/19Cassiopea announces results of ordinary and extraordinary shareholders meetin..
TE
02/08Cassiopea announces 2018 Results in line with expectations
TE
2018Cassiopea announces attainment of all primary and secondary endpoints and hig..
TE
2018Cassiopea enters into loan agreement with Cosmo Pharmaceuticals NV
TE
2018CASSIOPEA : Command and control system
AQ
2018Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for C..
TE
2018Cassiopea Announces Results for First Half of 2018
TE
2018Cassiopea Announces Very Positive Interim Analysis Phase 2 Results for Breezu..
TE
2018CASSIOPEA SPA : half-yearly earnings release
2018EUROPE : European shares extend recovery rally as oil stocks lead
RE
More news
Analyst Recommendations on CASSIOPEA SPA
More recommendations
Sector news : Specialty & Advanced Pharmaceuticals
01:55aEISAI : starts phase 3 trials for second Alzheimer's drug after first's failure
RE
01:38aUPS eyes in-home health services with U.S. vaccine project
RE
03/21JOHNSON & JOHNSON : J&J to record $700 million charge related to abandoned drug ..
RE
03/21JOHNSON & JOHNSON : J&J to Impair Value of Investigational Antiviral Treatment A..
DJ
03/21CONATUS PHARMACEUTICALS : Shares Plummet After Emricasan Study Misses Primary En..
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Chart CASSIOPEA SPA
Duration : Period :
Cassiopea SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSIOPEA SPA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 70,0 €
Spread / Average Target 78%
EPS Revisions
Managers
NameTitle
Diana Harbort Chief Executive Officer & Executive Director
Jan Egbert de Vries Non-Executive Chairman
Marco Pasero Chief Operating Officer
Hans Christoph Tanner CFO, Head-Investor & Media Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CASSIOPEA SPA21.31%448
ABBVIE-11.88%118 641
MERCK KGAA11.41%14 801
KYOWA HAKKO KIRIN CO LTD16.03%11 494
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD25.41%9 799
JAZZ PHARMACEUTICALS PLC9.74%7 621